Nanotechnology Now - Press Release: "Hana Biosciences to Present Data On Marqibo, Its Lead Novel Anti-Cancer Compound, At 2008 American Society of Hematology (ASH) Meeting"

Home > Press > Hana Biosciences to Present Data On Marqibo, Its Lead Novel Anti-Cancer Compound, At 2008 American Society of Hematology (ASH) Meeting

Abstract:
Hana Biosciences (Nasdaq:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced that several presentations related to the Company's lead anti-cancer compound, Marqibo(r) (vincristine sulfate injection, OPTISOME(tm)), will be presented at the upcoming annual meeting of the American Society of Hematology (ASH) in San Francisco during December 6-9, 2008.

Hana Biosciences to Present Data On Marqibo, Its Lead Novel Anti-Cancer Compound, At 2008 American Society of Hematology (ASH) Meeting

SOUTH SAN FRANCISCO, CA | Posted on December 1st, 2008

The following posters will be presented in Hall A of the Moscone Center at the ASH annual meeting. Text of these abstracts can be viewed on the ASH website at www.hematology.org.

* In Vivo Anti-Tumor Efficacy of Vincristine Sulfate Liposomes
Injection (VSLI, Marqibo) in Multiple Myeloma (abstract #2760;
Sunday, Dec. 7, 6:00 PM)

* Peripheral Neuropathy Profile of Vincristine Sulfate Liposomes
Injection (VSLI, Marqibo), a Nanoparticle Vincristine Formulation,
in Adult Subjects with Relapsed/Refractory Acute Lymphoblastic
Leukemia (ALL) and Non-Hodgkin's Lymphoma (NHL) (abstract #2928;
Monday, Dec. 8, 5:30 PM)

* Phase 1 Study of Weekly Vincristine Sulfate (VCR) Liposomes
Injection (VSLI, Marqibo) Plus Dexamethasone in Adults with Relapsed
or Refractory Acute Lymphoblastic Leukemia (ALL) (abstract #2930;
Monday, Dec. 8, 5:30 PM)

####

About Hana Biosciences
Hana Biosciences, Inc. (Nasdaq:HNAB) is a South San Francisco, CA-based biopharmaceutical company focused on acquiring, developing, and commercializing innovative products to strengthen the foundation of cancer care. The company is committed to creating value by building a best-in-class team, accelerating the development of lead product candidates, expanding its pipeline by being an alliance partner of choice, and nurturing a unique company culture.

For more information, please click here

Contacts:
Hana Biosciences
Investor & Media Contacts:
Investor Relations Team
(650) 588-6641

Invigorate Communications
Gregory Gin
(908) 376-7737

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark: